Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The NOD mouse model (1)
3. Pancreatic byopsy from NOD mouse
4. The NOD mouse model (2)
5. Other NOD characteristics
6. Immune cascade
7. Type 1 diabetes: mice versus humans
8. Diabetes prevention in the NOD mouse (1)
9. Anti-CD3 therapy in NOD mice
10. Diabetes prevention in the NOD mouse (2)
11. Vitamin D effect on NOD mice
12. Diabetes prevention in the NOD mouse (3)
13. Diabetes prevention in humans (1)
14. Anti-CD3 in new-onset type 1 diabetes mellitus
15. C-peptide response in the anti-CD3 trial
16. Immune response in the anti-CD3 trial
17. Belgian-German anti-CD3 trial
18. Belgian anti-CD3 trial
19. Humanized anti-CD3 in T1D (1)
20. Humanized anti-CD3 in T1D (2)
21. Dosage differences in trials
22. C-peptide positivity required in the Belgian trial
23. HbA1c in anti-CD3 trial
24. C-peptide/insulin dose in anti-CD3 trial (1)
25. C-peptide/insulin dose in anti-CD3 trial (2)
26. C-peptide/insulin dose in anti-CD3 trial (3)
27. Conclusions of anti-CD3 trial
28. Safety and immunological changes
29. Flu-like syndrome during treatment
30. Mononucleosis-like syndrome after treatment
31. Anti-CD3 treatment results
32. Diabetes prevention in humans (2)
33. The ENDIT trial
34. Diabetes prevention in NOD: Ag specific (1)
35. Effect of insulin on diabetes in NOD
36. Diabetes prevention in NOD: Ag specific (2)
37. Diabetes prevention in humans: Ag specific (1)
38. DPT-1 trial map
39. DPT-1 intervention protocols
40. DPT-1 staging scheme
41. Parenteral antigen protocol
42. DPT-1 screening results
43. DPT-1 study: time to diabetes by treatment
44. DPT-1 study: MMTT peak C-peptide by treatment
45. Oral antigen protocol
46. Diabetes prevention in humans: Ag specific (2)
47. DiaPep277 trial
48. Risk of shock in autoantigen vaccination
49. Insulin peptide induction of anaphylaxis
50. Anaphylaxis in NOD
51. Incidence of HEL-induced shock: strain specific
52. Diabetes prevention in humans: Ag specific (3)
53. Trial to reduce IDDM in genetically at risk
54. Pilot trial by the TRIGR group
55. Vitamin D and type 1 diabetes in humans
56. Epidemiological studies of vitamin D influence
57. Experimental design
58. Vitamin D and diabetes incidence
59. Conclusions
60. We can prevent type 1 diabetes in animals

Topics Covered

• Type 1 diabetes is an autoimmune disease characterized by an immune destruction of the insulin producing beta-cells in the islets of Langerhans of the pancreas
• As these cells are the only cells in the body that are able to synthesize and secrete insulin in a regulated manner, destruction of these cells renders the patient dependent on exogenous insulin administration for survival
• Interventions aimed at preventing the disease have not been successful until now, but lessons from the animal models open new perspectives

Links

Series:

• The World of Hormones

Categories:

• Immunology
• Metabolism & Nutrition

Therapeutic Areas:

• Cardiovascular & Metabolic
• Immunology & Inflammation

Talk Citation

Publication History

• Published on December 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Chantal Mathieu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.